[go: up one dir, main page]

WO1995005604A3 - Methods for the diagnosis of alzheimer's disease - Google Patents

Methods for the diagnosis of alzheimer's disease Download PDF

Info

Publication number
WO1995005604A3
WO1995005604A3 PCT/US1994/008903 US9408903W WO9505604A3 WO 1995005604 A3 WO1995005604 A3 WO 1995005604A3 US 9408903 W US9408903 W US 9408903W WO 9505604 A3 WO9505604 A3 WO 9505604A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
diagnosis
disease
methods
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/008903
Other languages
French (fr)
Other versions
WO1995005604A2 (en
Inventor
Ginger Johnson
Hossein A Ghanbari
Benjamin Wolozin
Carl R Merril
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Geriatrics Corp
US Department of Health and Human Services
Original Assignee
Molecular Geriatrics Corp
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Geriatrics Corp, US Department of Health and Human Services filed Critical Molecular Geriatrics Corp
Priority to AU75569/94A priority Critical patent/AU7556994A/en
Publication of WO1995005604A2 publication Critical patent/WO1995005604A2/en
Anticipated expiration legal-status Critical
Publication of WO1995005604A3 publication Critical patent/WO1995005604A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Electrochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method for the diagnosis of Alzheimer's Disease is disclosed. The method utilizes a unique set of proteins which are found to be altered in concentration in patients with Alzheimer's. The invention also relates to these proteins and their antibodies. Kits which can be used for the diagnostic test are also disclosed.
PCT/US1994/008903 1993-08-13 1994-08-15 Methods for the diagnosis of alzheimer's disease Ceased WO1995005604A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75569/94A AU7556994A (en) 1993-08-13 1994-08-15 Methods for the diagnosis of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10592293A 1993-08-13 1993-08-13
US08/105,922 1993-08-13

Publications (2)

Publication Number Publication Date
WO1995005604A2 WO1995005604A2 (en) 1995-02-23
WO1995005604A3 true WO1995005604A3 (en) 2001-09-13

Family

ID=22308530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/008903 Ceased WO1995005604A2 (en) 1993-08-13 1994-08-15 Methods for the diagnosis of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU7556994A (en)
WO (1) WO1995005604A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297244B2 (en) 2011-08-31 2016-03-29 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing comprising a coating of hydrogel-forming polymer
US9315721B2 (en) 2011-08-31 2016-04-19 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
ATE218583T1 (en) 1995-03-14 2002-06-15 Praecis Pharm Inc COMPOUNDS WITH AGGREGATION-MODULATING EFFECTS ON AMYLOID PROTEIN
EP0846269B1 (en) * 1995-08-16 2003-09-24 Aventis Pharmaceuticals Inc. A method of determining the degree of aggregation of the beta a4 peptide
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
FR2751412B3 (en) * 1996-07-17 1998-09-25 Valbiofrance METHODS OF IN VITRO DIAGNOSIS OF NEURODEGENERATIVE DISEASES AND KITS FOR THE IMPLEMENTATION OF THESE METHODS
US5919631A (en) * 1996-07-17 1999-07-06 Hoechst Marion Roussel, Inc. Method of determining the degree of aggregation of the β-A4 peptide
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
WO1998040748A1 (en) * 1997-03-14 1998-09-17 Neuromark Diagnosing neurologic disorders
JP4763135B2 (en) 1998-12-23 2011-08-31 メザイク プロプライエトリー リミティッド Assays for detecting binding partners
ES2290023T3 (en) 1999-03-04 2008-02-16 Praecis Pharmaceuticals Incorporated MODULATORS OF BETA-AMYLOID PEPTIDE AGGREGATION UNDERSTANDING D-AMINO ACIDS.
US9845427B2 (en) 2009-10-20 2017-12-19 Self-Suspending Proppant Llc Proppants for hydraulic fracturing technologies
US20140000891A1 (en) 2012-06-21 2014-01-02 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing
US9868896B2 (en) 2011-08-31 2018-01-16 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing
US9932521B2 (en) 2014-03-05 2018-04-03 Self-Suspending Proppant, Llc Calcium ion tolerant self-suspending proppants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008309A1 (en) * 1989-12-05 1991-06-13 New England Medical Center Hospitals, Inc. Methods for detection of neurodegenerative disease
EP0444856A2 (en) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for Alzheimer's disease
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
WO1993025911A1 (en) * 1992-06-17 1993-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosing alzheimer's disease and schizophrenia
WO1994002851A1 (en) * 1992-07-28 1994-02-03 University Of Cincinnati Clinical test for detection of alzheimer's disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008309A1 (en) * 1989-12-05 1991-06-13 New England Medical Center Hospitals, Inc. Methods for detection of neurodegenerative disease
EP0444856A2 (en) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for Alzheimer's disease
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
WO1993025911A1 (en) * 1992-06-17 1993-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosing alzheimer's disease and schizophrenia
WO1994002851A1 (en) * 1992-07-28 1994-02-03 University Of Cincinnati Clinical test for detection of alzheimer's disease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297244B2 (en) 2011-08-31 2016-03-29 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing comprising a coating of hydrogel-forming polymer
US9315721B2 (en) 2011-08-31 2016-04-19 Self-Suspending Proppant Llc Self-suspending proppants for hydraulic fracturing

Also Published As

Publication number Publication date
WO1995005604A2 (en) 1995-02-23
AU7556994A (en) 1995-03-14

Similar Documents

Publication Publication Date Title
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
GR3022287T3 (en) Detection of neurological disease or dysfunction
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
ATE223051T1 (en) METHOD FOR DIAGNOSIS OF BENCNIC PROSTATE DISEASES
AU5292290A (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
EP1011415A4 (en) NON-INVASIVE METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE IN MAN
DE3786200D1 (en) DIAGNOSTIC PROCEDURE FOR DETECTING LYMPHOMAS IN HUMANS.
CA2116348A1 (en) Sirs vaccine and diagnosis method
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
ATA328286A (en) CELL LINES AND METHOD FOR PRODUCING HUMAN MONOCLONAL ANTIBODIES AND KIT AND METHOD FOR DETERMINING THE PRESENCE OF P.AERUGINOSA
DK0433088T3 (en) Monoclonal antibodies that react with a human atheroma-associated antigen
ATE181422T1 (en) METHOD FOR DIAGNOSIS OF PREECLAMPSIA
DE3888998D1 (en) Method for the determination of an antibody in human body fluids.
DE69333412D1 (en) TRANSITIONAL STATE ANALOGA DES KOKAINS, THEIR USE FOR THE PRODUCTION OF CATALTIC ANTIBODIES AGAINST COCOIN AND THE USE THEREOF IN DIAGNOSIS AND THERAPY
AU5153398A (en) Diagnostic method for the detection of alzheimer's disease in living patients
EP0873421A4 (en) Diagnostic procedure and kit of reagents for determining the Rh blood group genotype
DE68921374D1 (en) Monoclonal antibody to human manganese superoxide dismutase, process for its preparation, test reagent, kit and test method using the same, process for diagnosing human ovarian cancer and heart attack.
ATE86633T1 (en) SNRNP-A ANTIGEN AND FRAGMENTS THEREOF.
AU2579995A (en) Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
ATE93629T1 (en) METHODS FOR DIAGNOSIS IN VITRO OF HUMAN CYTOMEGALOVIRUS INFECTIONS AND USE OF MONOCLONAL ANTIBODIES TO CYTOMEGALOVIRUS REACTIVE WITH A CYTOMEGALOVIRUS-INDUCED PROTEIN KINASE.
CA2067797A1 (en) Production and use of human nm23 protein and antibodies therefor
FI910324A7 (en) Methods and test kits for the detection of human leukocyte antigen DNA
ATE103989T1 (en) MONOCLONAL ANTIBODIES TO E7 PROTEIN OF HUMAN PAPILLOMVIRUS TYPE 16, PROCESS FOR THEIR PRODUCTION AND THEIR USE.
DE3789181D1 (en) A new test method and method for producing the enzyme using NAD synthetase.
AU1397495A (en) Diagnostic tests and reagents for detecting risk of alzheimer's disease and stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG